Zymeworks Inc. (ZYME) Q3 2025 10-Q Quarterly Report
Zymeworks Inc. (ZYME) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Zymeworks Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: European Commission granted conditional marketing authorization of Ziihera® in July 2025, contingent on ongoing Phase 3 trial results
- • Material update: FDA accelerated approval of Ziihera® in Nov 2024 requires confirmatory trial; failure may lead to market removal impacting royalties
Get deeper insights on Zymeworks Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.